| 129.36 -6.32 (-4.66%) | 11-20 16:00 | |||||||||||||
|
|
| Short term | ||||
| Mid term | ||||
| Targets | 6-month : | 173.82 | 1-year : | 192.47 |
| Resists | First : | 148.82 | Second : | 164.78 |
| Pivot price | 137.13 |
|||
| Supports | First : | 123 | Second : | 102.33 |
| MAs | MA(5) : | 134.39 |
MA(20) : | 138.73 |
| MA(100) : | 192.57 |
MA(250) : | 189.58 |
|
| MACD | MACD : | -7.8 |
Signal : | -8.8 |
| %K %D | K(14,3) : | 35.3 |
D(3) : | 41 |
| RSI | RSI(14): 32.8 |
|||
| 52-week | High : | 260.19 | Low : | 123 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ AXSM ] has closed above bottom band by 12.5%. Bollinger Bands are 31% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 135.5 - 136.25 | 136.25 - 136.86 |
| Low: | 125.87 - 126.91 | 126.91 - 127.75 |
| Close: | 127.83 - 129.37 | 129.37 - 130.62 |
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Sat, 21 Nov 2026
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Has Average Price Target of $266.21 - MarketBeat
Fri, 20 Nov 2026
Axsome Therapeutics, Inc. (AXSM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Mon, 16 Nov 2026
Axsome Therapeutics Sees AUVELITY Prescription Surge After Alzheimer’s Agitation Launch - TradingView
Mon, 02 Nov 2026
Axsome Therapeutics (AXSM) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Finance
Tue, 27 Oct 2026
Axsome Therapeutics, Inc. (AXSM) - What Are Researchers Saying About This Stock? - MarketBeat
Mon, 05 Oct 2026
Why Baird Sees Growth Potential in Axsome Therapeutics, Inc. (AXSM) - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 53 (M) |
| Shares Float | 45 (M) |
| Held by Insiders | 15 (%) |
| Held by Institutions | 74.4 (%) |
| Shares Short | 3,110 (K) |
| Shares Short P.Month | 3,140 (K) |
| EPS | -3.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2 |
| Profit Margin | -18.2 % |
| Operating Margin | -5.2 % |
| Return on Assets (ttm) | -13.7 % |
| Return on Equity (ttm) | -175.6 % |
| Qtrly Rev. Growth | 51.9 % |
| Gross Profit (p.s.) | 15.33 |
| Sales Per Share | 16.45 |
| EBITDA (p.s.) | -2.91 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -82 (M) |
| Levered Free Cash Flow | -24 (M) |
| PE Ratio | -42.7 |
| PEG Ratio | 0 |
| Price to Book value | 64.35 |
| Price to Sales | 7.86 |
| Price to Cash Flow | -83.22 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |